Loading...
ITCI logo

Intra-Cellular Therapies, Inc.NasdaqGS:ITCI Stock Report

Market Cap US$14.0b
Share Price
n/a
1Y97.8%
7D0.1%
1D-0.04%
Portfolio Value
​
View

Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Stock Report

Market Cap: US$14.0b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Intra-Cellular Therapies (ITCI) Stock Overview

A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. More details

ITCI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 71.6% below our estimate of its fair value

Earnings are forecast to grow 50.69% per year

Earnings have grown 10.9% per year over the past 5 years

Risk Analysis

Volatile share price over the past 3 months compared to the US market


ITCI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,625 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,625 investors already sharing narratives
View all narratives

Intra-Cellular Therapies, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Intra-Cellular Therapies
Historical stock prices
Current Share PriceUS$131.87
52 Week HighUS$131.98
52 Week LowUS$64.09
Beta0.70
1 Month Change2.86%
3 Month Change57.89%
1 Year Change97.80%
3 Year Change108.62%
5 Year Change762.46%
Change since IPO1,218.70%

Recent News & Updates

Seeking Alpha • Mar 05

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition

Summary Intra-Cellular Therapies' Caplyta shows strong sales growth and label expansion potential, making it a valuable acquisition for Johnson & Johnson at $14 billion. JNJ's acquisition of ITCI is strategic, replacing its aging Invega with Caplyta, which has patent protection until 2033 and ongoing clinical trials for new formulations. The $14 billion price tag is justified given Caplyta's advanced clinical stage, FDA approvals, and potential blockbuster status in the schizophrenia and bipolar disorder markets. Schizophrenia and MDD markets are substantial, with Caplyta positioned to capture significant market share, enhancing JNJ's portfolio amidst broader portfolio challenges. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Mar 05

Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition

Summary Intra-Cellular Therapies' Caplyta shows strong sales growth and label expansion potential, making it a valuable acquisition for Johnson & Johnson at $14 billion. JNJ's acquisition of ITCI is strategic, replacing its aging Invega with Caplyta, which has patent protection until 2033 and ongoing clinical trials for new formulations. The $14 billion price tag is justified given Caplyta's advanced clinical stage, FDA approvals, and potential blockbuster status in the schizophrenia and bipolar disorder markets. Schizophrenia and MDD markets are substantial, with Caplyta positioned to capture significant market share, enhancing JNJ's portfolio amidst broader portfolio challenges. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies

Summary Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion or $132 per share. Caplyta's peak sales potential exceeds $5 billion in the hands of J&J, driven by growth in schizophrenia, bipolar disorder, and the pending approval in major depressive disorder. The deal also brings Intra-Cellular Therapies' early-stage pipeline that adds to the long-term upside potential of the deal. Intellectual property risk on Caplyta is substantially reduced with last week's settlement with Sandoz, but not entirely eliminated as it does not stop other generic manufacturers from trying. I believe J&J is paying (at least) a fair price, with decent likelihood of creating substantial long-term value for the company. Read the full article on Seeking Alpha
Seeking Alpha • Dec 09

Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move

Summary CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it as an adjunctive therapy for major depressive disorder, addressing a significant unmet need. Lenrispodun, a PDE inhibitor, is in a phase 2 study for Parkinson's Disease, with potential data release by late 2025/early 2026, offering another blockbuster opportunity. Financially stable with $1 billion in cash and investments, but may raise funds in 2025 to support sales force expansion and R&D programs. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Peaking Back In On Intra-Cellular Therapies

Summary Intra-Cellular Therapies has shown significant progress since we last looked at it in November, with its stock rising nearly 30% since then and CAPLYTA prescriptions growing 36% YoY. CAPLYTA is also poised for FDA approval for major depressive disorder, potentially expanding its market significantly, with an sNDA submission expected in the second half of 2024. The company reported strong Q2 results, with revenues up 45% YoY and a reduced net loss, while analysts remain largely positive with multiple Buy ratings. However, despite positive developments, the stock appears fully valued, trading at over 10 times revenues and 100 times FY2025E EPS, with notable insider selling in August. An updated analysis around Intra-Cellular Therapies follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jun 19

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Summary Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027. I recommend buying ITCI stock as a high-risk, high-return component of a barbell investment strategy. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Summary Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achieved with statistical significance. The Major Depressive Disorder market across the eight major markets is expected to reach $9.6 billion by 2029. Results from the second phase 3 study using lumateperone as an adjunctive therapy for MDD, Study 502, are expected to be released in Q2 of 2024. With two positive phase 3 studies achieved, there is the potential for submission of New Drug Application of lumateperone to the FDA for the treatment of patients with MDD in the 2nd half of 2024. Read the full article on Seeking Alpha

Shareholder Returns

ITCIUS PharmaceuticalsUS Market
7D0.1%-1.3%0.8%
1Y97.8%47.9%20.2%

Return vs Industry: ITCI exceeded the US Pharmaceuticals industry which returned -1.3% over the past year.

Return vs Market: ITCI exceeded the US Market which returned 6.1% over the past year.

Price Volatility

Is ITCI's price volatile compared to industry and market?
ITCI volatility
ITCI Average Weekly Movement10.6%
Pharmaceuticals Industry Average Movement9.2%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: ITCI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ITCI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2002860Sharon Mateswww.intracellulartherapies.com

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder.

Intra-Cellular Therapies, Inc. Fundamentals Summary

How do Intra-Cellular Therapies's earnings and revenue compare to its market cap?
ITCI fundamental statistics
Market capUS$14.03b
Earnings (TTM)-US$74.68m
Revenue (TTM)US$680.85m
20.6x
P/S Ratio
-187.8x
P/E Ratio

Is ITCI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ITCI income statement (TTM)
RevenueUS$680.85m
Cost of RevenueUS$293.08m
Gross ProfitUS$387.77m
Other ExpensesUS$462.44m
Earnings-US$74.68m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin56.95%
Net Profit Margin-10.97%
Debt/Equity Ratio0%

How did ITCI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/01 10:40
End of Day Share Price 2025/04/01 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intra-Cellular Therapies, Inc. is covered by 6 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert HazlettBTIG
Jason ButlerCitizens JMP Securities, LLC
Corinne JohnsonGoldman Sachs